As the Democratic Republic of the Congo confronts , researchers have begun a vaccine trial aimed at closing a gap in protection. By October 27, reports citing the World Health Organization counted more than 10,000 cases and nearly 5,000 deaths. The outbreak is caused by the Bundibugyo virus, one of several viruses that cause Ebola disease. No vaccine is currently approved specifically against it.
The new study, called Tumaini, meaning “hope” in Swahili, . Congolese researchers and the University of Antwerp are leading the trial with international partners. The first vaccine being tested is , already licensed against a different Ebola virus commonly called Zaire ebolavirus. .
Health workers began receiving Ervebo in September. The new trial will help answer whether vaccination protects people exposed to Bundibugyo. Researchers are using “ring vaccination,” focusing on people identified through investigations of patients’ recent contacts. The study can evaluate several vaccines, and researchers also plan to study two vaccines designed for Bundibugyo: and another from .
For vaccine history, this is another step toward protecting people against the different viruses behind Ebola outbreaks. But starting a trial doesn’t prove a vaccine works. Researchers must establish its safety and effectiveness against Bundibugyo, while teams continue to find cases, monitor exposed people, prevent infections, and provide care. Those measures remain essential as research continues.